Obesity is one of the most common health problems today, due to poor eating habits and lack of physical activity that predominate among citizens. A study conducted by researchers at the University of Texas at San Antonio (USA) has developed a new inhibitor that could be effective in treating obesity and preventing cardiovascular disease.
The new drug’s mechanism of action is based on blocking the effects of cytochrome P450 8B1, which is an enzyme that creates cholic acid in the body and has been linked to cholesterol absorption and obesity. This drug could help treat metabolic problems related to obesity, diabetes or heart disease.
The research tests, which have been published in the journal Steroids, have been carried out on mice that were administered the drug for a period of seven days and subjected to a diet rich in fat and sucrose. The results obtained in the blood tests of the animals indicated that despite the poor eating habits, there was a reduction in blood glucose levels and their body weight did not change.
The drug contributes to a healthier metabolic profile
The findings of this study have shown how this drug based on the P450 8B1 inhibitor could contribute to a healthier metabolic profile, and could also be the first step in developing a new therapeutic strategy focused on the treatment of insulin resistance. related to obesity.
Mice taking the new drug had lower blood glucose levels and no weight change despite eating a high-fat, sucrose-rich diet.
“As an exercise physiologist, I truly believe that exercise is the best medicine to fight NCDs. Unfortunately, adherence to exercise is quite low and the prevalence of obesity is continually increasing. Based on promising data, I have high hopes of continuing to test Dr. Yoshimoto’s inhibitor,” says Eunhee Chung, one of the research collaborators.
If its effectiveness is proven in new studies, this drug could improve the health and well-being of society, especially marked by the obesity epidemic, a disease that can cause other health problems that can be fatal.
.
